• DOI:10.1080/21678421.2016.1221971
Corpus ID: 4584977.oa

Phase I clinical trial of safety of L-serine for ALS patients.

@article{Levine2017PhaseIC,
  title={Phase I clinical trial of safety of L-serine for ALS patients.},
  author={Todd D. Levine and Robert G. Miller and Walter G. Bradley and Dan H. Moore and David S. Saperstein and Lynne E Flynn and Jonathan S. Katz and Dallas A Forshew and J S Metcalf and Sandra Anne Banack and Paul Alan Cox},
  journal={Amyotrophic lateral sclerosis & frontotemporal degeneration},
  year={2017},
  volume={18 1-2},
  pages={
          107-111
        }
}

Todd D. Levine, Robert G. Miller, +8 authors Paul Alan Cox

Published in

Amyotrophic lateral sclerosis…

2017

Medicine

We performed a randomized, double-blind phase I clinical trial for six months on the effects of oral L-serine in patients with ALS. The protocol called for enrollment of patients with a diagnosis of probable or definite ALS, age 18-85 years, disease duration of less than three years and forced vital capacity (FVC) ≥ 60%. Patients were randomly assigned to four different oral twice-daily dose regimens (0.5, 2.5, 7.5, or 15 g/dose). Blood, urine and CSF samples, ALS Functional Rating Scale… CONTINUE READING

View on PubMed

Open Access

Save to Library

Create Alert

Cite

Launch Research Feed

Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv